Development of a clinical nomogram for prediction of response to neoadjuvant chemotherapy in patients with advanced gastric cancer

Figure 1 Screening of variables based on least absolute shrinkage and selection operator regression. A: Variation characteristics of the coefficient of variables; B: Selection process of the optimum value of the parameter λ in the least absolute shrinkage and selection operator regression model by cross-validation method.

Figure 2 Nomogram for predicting response to neoadjuvant chemotherapy. CA724: Carbohydrate antigen 724; NAC: Neoadjuvant chemotherapy.

Figure 3 Calibration curve for the nomogram model. NAC: Neoadjuvant chemotherapy.

Figure 4 Decision curve analysis analyzed clinical utility of the nomogram. The y-axis represented net benefits, and the x-axis measured threshold probability. The horizontal solid line indicated the advantage for patients not receiving neoadjuvant chemotherapy (NAC), the oblique solid line represented the advantage for patients receiving NAC, and the diagonal dotted line (nomogram) indicated survival based on nomogram scores to resolve whether a patient should receive NAC. A treatment strategy was superior if it had the highest value compared to other models, including two simple strategies, such as performing NAC for all patients (sloping solid line) or performing primary surgery first (horizontal solid line).